Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme

Stock Information for Marizyme Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marizyme Inc

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)
Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto
Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.